Skip Navigation


Lynne Wagner, Ph.D.Wake Forest School of Medicine

Lynne Wagner, Ph.D.


Contact Information

Academic: 336-713-1478 | Department: 336-716-2011


Education & Training

  • B.S., University of Michigan/Ann Arbor, 1992
  • M.A., Depaul University, 1995
  • Ph.D., Depaul University, 1997
Lynne Wagner, Ph.D.

Lynne Wagner, Ph.D.

Professor, Social Sciences & Health Policy
Comprehensive Cancer Center

Research Interests

Neoplasms; Quality of Life; Antineoplastic Agents; Breast Neoplasms; Depressive Disorder, Major
More »

Contact Information

Academic: 336-713-1478 | Department: 336-716-2011


Recent Publications

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. Zhao F, Cella D, Manola J, DiPaola RS, Wagner LI, Haas NSB.. Support Care Cancer. 2018;26(6):1889-1895.

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on. Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D.. Breast Cancer Res Treat. 2018;():.

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. Yeruva SLH, Zhao FM, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, Sparano JA, Connolly RM.. NPJ Breast Cancer. 2018;4():1.

Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805. Estabrook R, Cella D, Zhao F, Manola J, DiPaola RS, Wagner LI, Haas NB.. Qual Life Res. 2018;27(6):1589-1597.

Screening for depression in cancer patients receiving radiotherapy: feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. Wagner LI, Pugh SL, Small W Jr, Kirshner J, Sidhu K, Bury MJ, DeNittis AS, Alpert TE, Tran B, Bloom BF, Mai J, Yeh A, Sarma K, Becker M, James J, Bruner DW.. Cancer. 2017;123(3):485-493.

E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B.. J Clin Oncol. 2017;35(5):490-497.

Coping strategies tailored to the management of fear of recurrence and adaptation for E-health delivery: the FoRtitude intervention. Wagner LI, Duffecy J, Penedo F, Mohr DC, Cella D.. Cancer. 2017;123(6):906-910.

Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. Apple AC, Ryals AJ, Alpert KI, Wagner LI, Shih PA, Dokucu M, Cella D, Penedo FJ, Voss JL, Wang L.. Neuroimage Clin. 2017;14():685-691.

The connect MM registry: impact of the cytogenetic abnormality T (11;14) on survival outcomes in African American and non-African American patients with newly diagnosed multiple myeloma [abstract]. Gasparetto CJ, Abonour R, Jagannath S, Durie BG, Shah JJ, Narang M, Terebelo HR, Toomey K, Hardin JW, Wagner L, Srinivasan S, Kitali A, Flick ED, Zafar F, Agarwal A, Rifkin RM.. Haematologica. 2017;102(Suppl 2):116.

Assessment of the impact of post-autologous stem cell transplant maintenance therapy on survival outcomes in patients with newly diagnosed multiple myeloma in the community-based connect MM registry [abstract]. Jagannath S, Abonour R, Durie BG, Shah JJ, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Wagner L, Agarwal A, Srinivasan S, Kitali A, Zafar F, Sturniolo M, Rifkin RM.. Haematologica. 2017;102(Suppl 2):507.

Analysis of the connect MM registry: treatment outcomes and healthcare resource utilitzation in patients with newly diagnosed multiple myeloma who received lenalidomide maintenance or no maintenance [abstract]. Rifkin RM, Jagannath S, Durie BG, Shah JJ, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Wagner L, Parikh K, Abouzaid S, Srinivasan S, Kitali A, Zafar F, Abonour R.. Haematologica. 2017;102(Suppl 2):523-524.

Mutational landscapes of smoking-related cancers in Caucasians and African Americans: precision oncology perspectives at Wake Forest Baptist Comprehensive Cancer Center. Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC,.. Theranostics. 2017;7(11):2914-2923.

Next steps for adolescent and young adult oncology workshop: an update on progress and recommendations for the future. Smith AW, Seibel NL, Lewis DR, Albritton KH, Blair DF, Blanke CD, Bleyer WA, Freyer DR, Geiger AM, Hayes-Lattin B, Tricoli JV, Wagner LI, Zebrack BJ.. Cancer. 2016;122(7):988-999.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS.. Lancet. 2016;387(10032):2008-2016.

E2112: randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group [abstract]. Connolly R, Zhao F, Miller K, Tevaarwerk A, Wagner L, Lee M, Murray J, Gray R, Piekarz R, Zujewski JA, Sparano J.. Cancer Res. 2016;76(Suppl 4):OT2-01-04.

Quality of life difficulties in partners of young breast cancer survivors [abstract]. Champion V, Cohee AA, Monahan P, Stump TE, Miller K, Wagner L, Cella D, Sledge G.. J Clin Oncol. 2016;34(3 Suppl):188.

Care for a patient with cancer as a project: management of complex task interdependence in cancer care delivery. Trosman JR, Carlos RC, Simon MA, Madden DL, Gradishar WJ, Benson AB III, Rapkin BD, Weiss ES, Gareen IF, Wagner LI, Khan SA, Bunce MM, Small A, Weldon CB.. J Oncol Pract. 2016;12(11):1101-1113.

Prospective validation of a 21-gene expression assay in breast cancer. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL,.. N Engl J Med. 2015;373(21):2005-2014.

Implementation of distress screening in an oncology setting. Pearman T, Garcia S, Penedo F, Yanez B, Wagner L, Cella D.. J Community Support Oncol. 2015;13(12):423-428.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  25 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.